Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
7(64%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
4
36%
Ph phase_3
2
18%
Ph phase_1
5
45%

Phase Distribution

5

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
5(45.5%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(3)

Detailed Status

Recruiting6
Completed3
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
7
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (45.5%)
Phase 24 (36.4%)
Phase 32 (18.2%)

Trials by Status

recruiting655%
active_not_recruiting19%
completed327%
not_yet_recruiting19%

Recent Activity

7 active trials
Showing 5 of 11
active_not_recruitingphase_1

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

NCT06646055
recruitingphase_1

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

NCT07377045
recruitingphase_3

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

NCT07238283
recruitingphase_2

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

NCT07043270
recruitingphase_2

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT05969171
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06646055Phase 1

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Active Not Recruiting
NCT07377045Phase 1

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

Recruiting
NCT07238283Phase 3

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

Recruiting
NCT07043270Phase 2

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Recruiting
NCT05969171Phase 2

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Recruiting
NCT05218889Phase 1

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Recruiting
NCT06621095Phase 2

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

Not Yet Recruiting
NCT02827201Phase 2

FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine

Completed
NCT05751850Phase 3

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Recruiting
NCT02574663Phase 1

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Completed
NCT02174887Phase 1

Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11